BR112016015766A2 - Regime de dosagem de trimaltol férrico - Google Patents
Regime de dosagem de trimaltol férricoInfo
- Publication number
- BR112016015766A2 BR112016015766A2 BR112016015766A BR112016015766A BR112016015766A2 BR 112016015766 A2 BR112016015766 A2 BR 112016015766A2 BR 112016015766 A BR112016015766 A BR 112016015766A BR 112016015766 A BR112016015766 A BR 112016015766A BR 112016015766 A2 BR112016015766 A2 BR 112016015766A2
- Authority
- BR
- Brazil
- Prior art keywords
- trimaltol
- ferric
- dosage regime
- relates
- anemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201400171A GB201400171D0 (en) | 2014-01-06 | 2014-01-06 | Dosage regimen |
| GB201418708A GB201418708D0 (en) | 2014-10-21 | 2014-10-21 | Dosage regimen |
| PCT/IB2015/050098 WO2015101971A1 (en) | 2014-01-06 | 2015-01-06 | Dosage regimen of ferric trimaltol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016015766A2 true BR112016015766A2 (pt) | 2017-08-08 |
Family
ID=52432872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016015766A BR112016015766A2 (pt) | 2014-01-06 | 2015-01-06 | Regime de dosagem de trimaltol férrico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10179120B2 (https=) |
| EP (1) | EP3091974B1 (https=) |
| JP (2) | JP6556753B2 (https=) |
| KR (1) | KR102351422B1 (https=) |
| CN (2) | CN106413706A (https=) |
| AU (1) | AU2015204192B2 (https=) |
| BR (1) | BR112016015766A2 (https=) |
| CA (1) | CA2934836C (https=) |
| ES (1) | ES2785391T3 (https=) |
| IL (1) | IL246613B (https=) |
| SI (1) | SI3091974T1 (https=) |
| WO (1) | WO2015101971A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179120B2 (en) | 2014-01-06 | 2019-01-15 | Iron Therapeutics Holdings Ag | Dosage regimen of ferric trimaltol |
| GB201418710D0 (en) * | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
| WO2017167963A1 (en) | 2016-03-31 | 2017-10-05 | Medical Research Council | Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides |
| WO2017167970A1 (en) | 2016-03-31 | 2017-10-05 | Medical Research Council | Methods for producing ferric maltol compositions from ferrous hydroxides |
| AU2017242905B2 (en) | 2016-03-31 | 2020-10-22 | Shield TX (UK) Limited | Methods for producing ferric maltol compositions from elemental iron |
| CA3019478C (en) | 2016-03-31 | 2024-02-13 | United Kingdom Research And Innovation | Ferric maltol compositions for use in the treatment or prevention of cancer and tumours |
| GB2553099A (en) * | 2016-08-19 | 2018-02-28 | Shield Tx Uk Ltd | Use |
| IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
| CA3280511A1 (en) | 2024-07-18 | 2026-03-01 | Malian Biologicals Gmbh | Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases and iron supplementation in neurodevelopmental or psychiatric disorder |
| GB202414014D0 (en) | 2024-09-24 | 2024-11-06 | Shield Tx Uk Ltd | Use of ferric trimaltol in treating of preventing iron deficiency |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1150213B (it) * | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| SU1676626A1 (ru) * | 1989-05-17 | 1991-09-15 | Тюменский государственный медицинский институт | Способ лечени железодефицитных анемий |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| AU6010696A (en) | 1995-06-10 | 1997-01-09 | Vitra Pharmaceuticals Ltd | Iron compounds, compositions, methods of making the same and uses thereof |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| US7135196B2 (en) | 2000-09-19 | 2006-11-14 | Vitra Pharmaceuticals Limited | Iron compositions |
| US20050118291A1 (en) * | 2003-09-10 | 2005-06-02 | Mian-Ying Wang | Formulations and methods for treating breast cancer with Morinda citrifolia and methylsulfonymethane |
| EP1877094A1 (en) * | 2005-05-03 | 2008-01-16 | Innozen, Inc. | Edible film for transmucosal delivery of nutritional supplements |
| EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| US20070111936A1 (en) * | 2005-11-15 | 2007-05-17 | Vladimir Pak | Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer |
| GB0808835D0 (en) * | 2008-05-15 | 2008-06-18 | Vitra Pharmaceuticals Ltd | Therapeutic compositions |
| GB201101370D0 (en) | 2011-01-27 | 2011-03-09 | Iron Therapeutics Holdings Ag | Process |
| JP5856725B2 (ja) * | 2011-08-02 | 2016-02-10 | 和夫 酒井 | うつ病治療用または予防用医薬組成物 |
| US10179120B2 (en) | 2014-01-06 | 2019-01-15 | Iron Therapeutics Holdings Ag | Dosage regimen of ferric trimaltol |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
-
2015
- 2015-01-06 US US15/110,003 patent/US10179120B2/en active Active
- 2015-01-06 KR KR1020167021033A patent/KR102351422B1/ko active Active
- 2015-01-06 WO PCT/IB2015/050098 patent/WO2015101971A1/en not_active Ceased
- 2015-01-06 ES ES15701588T patent/ES2785391T3/es active Active
- 2015-01-06 SI SI201531165T patent/SI3091974T1/sl unknown
- 2015-01-06 JP JP2016562082A patent/JP6556753B2/ja active Active
- 2015-01-06 EP EP15701588.4A patent/EP3091974B1/en active Active
- 2015-01-06 BR BR112016015766A patent/BR112016015766A2/pt not_active Application Discontinuation
- 2015-01-06 CA CA2934836A patent/CA2934836C/en active Active
- 2015-01-06 CN CN201580005412.7A patent/CN106413706A/zh active Pending
- 2015-01-06 CN CN202111268204.XA patent/CN114010629A/zh active Pending
- 2015-01-06 AU AU2015204192A patent/AU2015204192B2/en active Active
-
2016
- 2016-07-05 IL IL246613A patent/IL246613B/en active IP Right Grant
-
2019
- 2019-04-05 JP JP2019072643A patent/JP2019131592A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019131592A (ja) | 2019-08-08 |
| IL246613B (en) | 2020-05-31 |
| CN114010629A (zh) | 2022-02-08 |
| US10179120B2 (en) | 2019-01-15 |
| JP2017501235A (ja) | 2017-01-12 |
| IL246613A0 (en) | 2016-08-31 |
| KR102351422B1 (ko) | 2022-01-13 |
| WO2015101971A1 (en) | 2015-07-09 |
| CA2934836A1 (en) | 2015-07-09 |
| AU2015204192A1 (en) | 2016-07-07 |
| CA2934836C (en) | 2022-03-22 |
| SI3091974T1 (sl) | 2020-08-31 |
| JP6556753B2 (ja) | 2019-08-07 |
| ES2785391T3 (es) | 2020-10-06 |
| US20160324822A1 (en) | 2016-11-10 |
| EP3091974A1 (en) | 2016-11-16 |
| KR20160105499A (ko) | 2016-09-06 |
| AU2015204192B2 (en) | 2020-03-26 |
| CN106413706A (zh) | 2017-02-15 |
| EP3091974B1 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016015766A2 (pt) | Regime de dosagem de trimaltol férrico | |
| MX2019004500A (es) | Terapia de combinación para la inhibición de componente de complemeto (c3). | |
| UA116196C2 (uk) | Синтетичний міметик апеліну для лікування серцевої недостатності | |
| TN2019000210A1 (en) | Antitumoral compounds | |
| NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
| BR112012001372A2 (pt) | comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia. | |
| PH12017500639A1 (en) | Neuroactive compounds and methods of use thereof | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
| PH12016501965A1 (en) | S1p modulator immediate release dosage regimen | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| NZ761519A (en) | Nlrp3 modulators | |
| MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| TW201713333A (en) | Methods of treating a neurodegenerative disease | |
| TN2015000558A1 (en) | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps) | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
| PH12017500910A1 (en) | Use of sigma receptor ligands in osteoarthritis | |
| MX2017004723A (es) | Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica. | |
| PH12017501897A1 (en) | 2-thiopyrimidinones | |
| MX2014008336A (es) | Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SHIELD TX (UK) LIMITED (GB) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |